

# Larry Mark Fisher

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3435532/larry-mark-fisher-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

47  
papers

2,462  
citations

27  
h-index

49  
g-index

52  
ext. papers

2,673  
ext. citations

10.3  
avg, IF

4.46  
L-index

#	Paper	IF	Citations
47	Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 6329-6357	8.3	13
46	Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 7773-7816	8.3	13
45	Trapping of the transport-segment DNA by the ATPase domains of a type II topoisomerase. <i>Nature Communications</i> , <b>2018</b> , 9, 2579	17.4	12
44	Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from <i>Klebsiella pneumoniae</i> and comparison with a related <i>Streptococcus pneumoniae</i> complex. <i>Acta Crystallographica Section D: Structural Biology</i> , <b>2016</b> , 72, 488-96	5.5	16
43	Exploring the active site of the <i>Streptococcus pneumoniae</i> topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones. <i>Open Biology</i> , <b>2016</b> , 6,	7	12
42	Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, 9411-23	20.1	14
41	Structure of an [open] clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, 9911-23	20.1	41
40	Structural basis of gate-DNA breakage and resealing by type II topoisomerases. <i>PLoS ONE</i> , <b>2010</b> , 5, e11338	3.7	127
39	Probing the differential interactions of quinazolidione PD 0305970 and quinolones with gyrase and topoisomerase IV. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 3822-31	5.9	74
38	Target specificity of the new fluoroquinolone besifloxacin in <i>Streptococcus pneumoniae</i> , <i>Staphylococcus aureus</i> and <i>Escherichia coli</i> . <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 443-50	5.1	60
37	Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. <i>Nature Structural and Molecular Biology</i> , <b>2009</b> , 16, 667-9	17.6	214
36	Methods to assay inhibitors of DNA gyrase and topoisomerase IV activities. <i>Methods in Molecular Medicine</i> , <b>2008</b> , 142, 11-23		25
35	Clerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage. <i>Nucleic Acids Research</i> , <b>2008</b> , 36, 5516-29	20.1	13
34	The difficult case of crystallization and structure solution for the ParC55 breakage-reunion domain of topoisomerase IV from <i>Streptococcus pneumoniae</i> . <i>PLoS ONE</i> , <b>2008</b> , 3, e3201	3.7	2
33	Breakage-reunion domain of <i>Streptococcus pneumoniae</i> topoisomerase IV: crystal structure of a gram-positive quinolone target. <i>PLoS ONE</i> , <b>2007</b> , 2, e301	3.7	29
32	Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases. <i>Nucleic Acids Research</i> , <b>2007</b> , 35, 6075-85	20.1	14
31	Clerocidin interacts with the cleavage complex of <i>Streptococcus pneumoniae</i> topoisomerase IV to induce selective irreversible DNA damage. <i>Nucleic Acids Research</i> , <b>2006</b> , 34, 1982-91	20.1	9

30	Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of <i>Mycobacterium tuberculosis</i> : functional analysis of mutant enzymes. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 104-12	5.9	160
29	First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from <i>Mycobacterium tuberculosis</i> . <i>Biochemical and Biophysical Research Communications</i> , <b>2006</b> , 348, 158-65	5.4	69
28	Novel symmetric and asymmetric DNA scission determinants for <i>Streptococcus pneumoniae</i> topoisomerase IV and gyrase are clustered at the DNA breakage site. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 14252-63	5.4	36
27	Ciprofloxacin dimers target gyrase in <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2004</b> , 48, 2108-15	5.9	22
26	<i>Mycobacterium tuberculosis</i> DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2004</b> , 48, 1281-8	5.9	189
25	Analysis of dual active fluoroquinolones in <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , <b>2003</b> , 52, 312-3; author reply 313-4	5.1	10
24	Dual activity of fluoroquinolones against <i>Streptococcus pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , <b>2003</b> , 51, 463-4; author reply 464-5	5.1	19
23	Small-colony mutants of <i>Staphylococcus aureus</i> allow selection of gyrase-mediated resistance to dual-target fluoroquinolones. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 2498-506	5.9	42
22	Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in <i>Streptococcus pneumoniae</i> : role of the C-5 group in target specificity. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 582-5	5.9	11
21	Cleavable-complex formation by wild-type and quinolone-resistant <i>Streptococcus pneumoniae</i> type II topoisomerases mediated by gemifloxacin and other fluoroquinolones. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 413-9	5.9	47
20	Quinolone resistance mutations in <i>Streptococcus pneumoniae</i> GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2001</b> , 45, 3140-7	5.9	56
19	Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells. <i>Molecular Pharmacology</i> , <b>2000</b> , 57, 784-91	4.3	17
18	Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha. <i>Molecular Pharmacology</i> , <b>2000</b> , 58, 560-8	4.3	20
17	Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in <i>Streptococcus pneumoniae</i> from topoisomerase IV to gyrase. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 320-5	5.9	87
16	Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2000</b> , 44, 3112-7	5.9	69
15	Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant <i>Streptococcus pneumoniae</i> displaying topoisomerase- and efflux-mediated resistance mechanisms. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1999</b> , 43, 2998-3000	5.9	32
14	<i>Streptococcus pneumoniae</i> DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1999</b> , 43, 1129-36	5.9	109
13	DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>1998</b> , 42, 2810-6	5.9	185

12	Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity. <i>Molecular Pharmacology</i> , <b>1997</b> , 52, 658-66	4.3	41
11	Molecular cloning and expression of the <i>Candida albicans</i> TOP2 gene allows study of fungal DNA topoisomerase II inhibitors in yeast. <i>Biochemical Journal</i> , <b>1997</b> , 324 ( Pt 1), 329-39	3.8	16
10	Complementation of temperature-sensitive topoisomerase II mutations in <i>Saccharomyces cerevisiae</i> by a human TOP2 beta construct allows the study of topoisomerase II beta inhibitors in yeast. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1997</b> , 39, 367-75	3.5	52
9	Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 15739-46	5.4	81
8	Biochemical and immunological characterization of mammalian DNA topoisomerase II. <i>Biochemical Society Transactions</i> , <b>1989</b> , 17, 528-529	5.1	6
7	Energetics of proline racemase: tracer perturbation experiments using [14C]proline that measure the interconversion rate of the two forms of free enzyme. <i>Biochemistry</i> , <b>1986</b> , 25, 2538-42	3.2	30
6	Energetics of proline racemase: rates, fractionation factors, and buffer catalysis in the oversaturated region. Nature of the interconversion of the two forms of free enzyme. <i>Biochemistry</i> , <b>1986</b> , 25, 2564-71	3.2	20
5	Energetics of proline racemase: transition-state fractionation factors for the two protons involved in the catalytic steps. <i>Biochemistry</i> , <b>1986</b> , 25, 2543-51	3.2	28
4	Energetics of proline racemase: racemization of unlabeled proline in the unsaturated, saturated, and oversaturated regimes. <i>Biochemistry</i> , <b>1986</b> , 25, 2529-37	3.2	51
3	Interaction of bleomycin A2 with deoxyribonucleic acid: DNA unwinding and inhibition of bleomycin-induced DNA breakage by cationic thiazole amides related to bleomycin A2. <i>Biochemistry</i> , <b>1985</b> , 24, 3199-207	3.2	83
2	DNase I hypersensitive sites in the chromatin of human mu immunoglobulin heavy-chain genes. <i>Nature</i> , <b>1983</b> , 306, 809-12	50.4	108
1	Energetics of triosephosphate isomerase: the nature of the proton transfer between the catalytic base and solvent water. <i>Biochemistry</i> , <b>1976</b> , 15, 5621-6	3.2	20